

# Liisa M Pelttari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1481355/publications.pdf>

Version: 2024-02-01

33  
papers

1,918  
citations

361413

20  
h-index

395702

33  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4572  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	6.3	106
2	Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 2692-2700.	5.1	19
3	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	6.4	15
4	Gene panel testing of breast and ovarian cancer patients identifies a recurrent <i>RAD51C</i> duplication. <i>Clinical Genetics</i> , 2018, 93, 595-602.	2.0	11
5	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	2.5	9
6	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
7	FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 217-226.	2.5	26
8	CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population. <i>BMC Cancer</i> , 2017, 17, 620.	2.6	29
9	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	1.9	71
10	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.2	174
11	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	3.8	19
12	Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 463-469.	2.5	24
13	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	1.9	111
14	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2016, 139, 2760-2770.	5.1	13
15	Screening of HELQ in breast and ovarian cancer families. <i>Familial Cancer</i> , 2016, 15, 19-23.	1.9	7
16	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
17	<i>RAD51B</i> in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	2.5	26
18	Assessment of variation in immunosuppressive pathway genes reveals <i>TGFBR2</i> to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	1.8	5

#	ARTICLE	IF	CITATIONS
19	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
20	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
21	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
22	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
23	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	2.5	28
24	RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. <i>SpringerPlus</i> , 2015, 4, 92.	1.2	21
25	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	1.4	15
26	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	12.8	63
27	Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	2.8	24
28	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	2.9	68
29	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
30	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15172-15177.	7.1	162
31	A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer: Table 1. <i>Journal of Medical Genetics</i> , 2012, 49, 429-432.	3.2	41
32	Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients. <i>BMC Cancer</i> , 2012, 12, 552.	2.6	8
33	RAD51C is a susceptibility gene for ovarian cancer. <i>Human Molecular Genetics</i> , 2011, 20, 3278-3288.	2.9	124